Elekta and the Netherlands Cancer Institute will combine their resources, knowledge, and expertise to accelerate improvements in Elekta’s Unity and linac solutions around imaging, personalized and adaptive radiotherapy, novel treatment delivery approaches, artificial intelligence and software solutions for improved workflow and decision support. In addition to research and the co-development of personalized treatment management software solutions, the Netherlands Cancer Institute will convert its treatment planning system to Elekta’s new treatment management solution, to which Philips has contributed.
Maurits Wolleswinkel, Elekta’s Chief Product Officer, says: “With this agreement, we will jointly further shape the future of radiation therapy through our research and product development relations. It demonstrates our commitment to partner-led innovation and to making the best cancer care accessible to everyone dealing with cancer.”
Anke van Mourik, Head of Medical Physics Radiotherapy, at the Netherlands Cancer Institute says: “The strength of this collaboration is the synergy in visions, the mutual innovative force and the close collaboration between research and the clinic. I am convinced that with our Elekta fleet and joint innovations, we can make a true impact on patient care.”
Jan Jakob Sonke, Professor of adaptive radiotherapy, at the Netherlands Cancer Institute, adds: “I am excited to build on our long history of collaboration, innovation and state-of-the-art solutions with Elekta. Together we can make a big step forward in personalized radiotherapy and provide the best possible outcomes for every patient.”
The Netherlands Cancer Institute is renowned for its innovation, such as the development of Cone Beam CT imaging technology. For more than 20 years, it has collaborated with Elekta. First, contributing to the development of Image Guided Radiation Therapy (IGRT) as well as ground-breaking 4D imaging, which was first implemented in Elekta Synergy®. A founding member of Elekta’s MR-Linac Consortium, the Netherlands Cancer Institute continues to make significant contributions to the Elekta Unity platform and, as part of this agreement, the Netherlands Cancer Institute will acquire a second Unity system, joining a growing list of centers adopting multiple Unity systems.
# # #
Photo caption:
Signing ceremony during ESTRO 2022 in Copenhagen.
Left to right: Jan Jakob Sonke, Professor of adaptive radiotherapy, NKI; Anke van Mourik, Head of Medical Physics Radiotherapy, NKI; Gustaf Salford, President and CEO, Elekta; Maarten Hovers, VP Northern Europe, Elekta
For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time
Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
Karlijn van Driel, NKI
Tel: +31 20 512 2850, e-mail: communicatie@nki.nl
Time zone: CET: Central European Time
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope.
Elekta is headquartered in Stockholm, Sweden, with offices in more than 120 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.
About the Netherlands Cancer Institute
The Netherlands Cancer Institute is among the world’s best comprehensive cancer centers, combining innovative fundamental, translational, and clinical research with dedicated patient care. Through this integrative approach, the department of Radiotherapy envisions to provide the most progressive treatment for every patient, thus contributing to the main goal: a cure for every cancer and excellent care for every patient. Our research institute gratefully acknowledges funding from the Dutch Ministry of Health, Welfare and Sport, the Dutch Cancer Society, and individual donors. For more information please visit our websites www.nki.nl and www.avl.nl.